May 14, 2020 / 10:44 AM / 16 days ago

BRIEF-Kaleido Biosciences Initiates Controlled Clinical Study Of Microbiome Metabolic Therapy Kb109 In Outpatients With Mild-To-Moderate COVID-19

May 14 (Reuters) - Kaleido Biosciences Inc:

* KALEIDO BIOSCIENCES INITIATES CONTROLLED CLINICAL STUDY OF MICROBIOME METABOLIC THERAPY KB109 IN OUTPATIENTS WITH MILD-TO-MODERATE COVID-19

* KALEIDO BIOSCIENCES INC - TOP-LINE DATA FROM STUDY OF APPROXIMATELY 350 PATIENTS EXPECTED IN Q4 2020

* KALEIDO BIOSCIENCES INC - SECOND CLINICAL STUDY EXPECTED TO INITIATE SHORTLY WITH SIMILAR DESIGN AND ADDITIONAL MICROBIOME ANALYSIS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below